US5284947A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Multiple drug resistance-attenuating compounds
Assignee: Abbott Laboratories
•
Filing: 1992-09-15
•
Granted: 1994-02-08
•
Expires: 2012-09-15
Abstract
Abstract A compound having the structural formula ##STR1## or a pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 is selected from the group consisting of hydrogen and loweracyl, and R 2 is selected from the group consisting of hydrogen, hydroxyl and methoxyl, as well as methods for the preparation and use thereof.
Inventors
- 👤 Sunil K. Kadam
- 👤 Patrick E. Humphrey
- 👤 Jill Hochlowski
- 👤 James B. McAlpine
- 👤 Marianna Jackson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 18:22
CPC Classifications
C; C07; C07D; C07D487/00; C07D487/22
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
42 words
A compound having the structural formula ##STR4## or a pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 is selected from the group consisting of hydrogen and loweracyl, and R 2 is selected from the group consisting of hydrogen, hydroxyl and methoxyl.
Claim 2
Dependent Claim
42 words
A compound having the structural formula ##STR4## or a pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 is selected from the group consisting of hydrogen and loweracyl, and R 2 is selected from the group consisting of hydrogen, hydroxyl and methoxyl.
Claim 3
Dependent Claim
11 words
A compound according to claim 1, wherein R 1 is loweracyl.
Claim 4
Dependent Claim
11 words
A compound according to claim 2, wherein R 2 is hydroxyl.
Claim 5
Dependent Claim
11 words
A compound according to claim 2, wherein R 1 is acetyl.
Claim 6
Dependent Claim
11 words
A compound according to claim 4, wherein R 2 is hydroxyl.
Claim 7
Dependent Claim
15 words
A compound selected from the group consisting of: ardeemin; 5-N-acetylardeemin; 5-N-acetyl-15b-β-hydroxyardeemin; 15b-β-hydroxyardeemin; 5-N-acetyl-15b-α-hydroxyardeemin; and 15b-β-methoxyardeemin.
Claim 8
Dependent Claim
15 words
A compound selected from the group consisting of: ardeemin; 5-N-acetylardeemin; 5-N-acetyl-15b-β-hydroxyardeemin; 15b-β-hydroxyardeemin; 5-N-acetyl-15b-α-hydroxyardeemin; and 15b-β-methoxyardeemin.
Claim 9
Dependent Claim
23 words
A pharmaceutical composition comprising a multiple drug resistance-attenuating amount of a compound according to claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
17 words
A pharmaceutical composition according to claim 7, additionally comprising a therapeutically effective amount of a cytotoxic agent.
Claim 11
Dependent Claim
23 words
A pharmaceutical composition comprising a multiple drug resistance-attenuating amount of a compound according to claim 6 in combination with a pharmaceutically acceptable carrier.
Claim 12
Dependent Claim
17 words
A pharmaceutical composition according to claim 9, additionally comprising a therapeutically effective amount of a cytotoxic agent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-02-07 | 1997-08-09 | 1998-02-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-02-07 | 2001-08-09 | 2002-02-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-02-07 | 2005-08-09 | 2006-02-08 | $7700.00 | Window Closed / Lapsed |